Research Article
Decreased Expression of CPEB3 Predicts a Poor Prognosis in Patients with Melanoma: A Study Based on TCGA Data
Table 1
Association of CPEB3 expression and clinicopathological features in melanoma.
| Characters | Level | Low expression of CPEB3, (%) | High expression of CPEB3, (%) | |
| | | 234 | 234 | | OS event (%) | Alive | 118 (51.3) | 128 (55.4) | 0.429 | Dead | 112 (48.7) | 103 (44.6) | | T stage (%) | T0 | 12 (6.0) | 11 (6.0) | <0.001 | T1 | 18 (9.0) | 23 (12.5) | | T2 | 31 (15.5) | 47 (25.5) | | T3 | 39 (19.5) | 51 (27.7) | | T4 | 100 (50.0) | 52 (28.3) | | N stage (%) | N0 | 118 (56.5) | 116 (57.4) | 0.235 | N1 | 35 (16.7) | 39 (19.3) | | N2 | 22 (10.5) | 27 (13.4) | | N3 | 34 (16.3) | 20 (9.9) | | M stage (%) | M0 | 212 (94.6) | 204 (94.4) | 1.000 | M1 | 12 (5.4) | 12 (5.6) | | Clinical stage (%) | Stage 0 | 4 (1.9) | 3 (1.5) | 0.418 | Stage I | 32 (15.0) | 44 (21.7) | | Stage II | 78 (36.6) | 62 (30.5) | | Stage III | 88 (41.3) | 82 (40.4) | | Stage IV | 11 (5.2) | 12 (5.9) | | Melanoma Clark level (%) | I | 4 (2.5) | 2 (1.3) | 0.017 | II | 7 (4.3) | 11 (7.0) | | III | 29 (18.0) | 47 (29.7) | | IV | 87 (54.0) | 81 (51.3) | | V | 34 (21.1) | 17 (10.8) | | Tumor status (%) | Tumor free | 102 (44.3) | 112 (48.7) | 0.400 | With tumor | 128 (55.7) | 118 (51.3) | | Gender (%) | Female | 92 (39.3) | 87 (37.2) | 0.704 | Male | 142 (60.7) | 147 (62.8) | | Age (median [IQR]) | | 58.0 [49.0, 71.0] | 58.0 [46.0, 71.0] | 0.329 | Height (median [IQR]) | | 170.0 [164.0, 176.0] | 172.0 [162.5, 179.5] | 0.304 | Weight (median [IQR]) | | 79.0 [67.0, 87.5] | 84.0 [70.0, 96.8] | 0.012 | BMI (median [IQR]) | | 26.0 [23.3, 30.1] | 27.5 [24.2, 33.2] | 0.026 | Tumor tissue site (%) | Extremities | 93 (43.5) | 102 (50.5) | 0.143 | Trunk | 95 (44.4) | 76 (37.6) | | Head and neck | 22 (10.3) | 15 (7.4) | | Other specify | 4 (1.9) | 9 (4.5) | | Ulceration (%) | No | 65 (40.6) | 80 (53.0) | 0.039 | Yes | 95 (59.4) | 71 (47.0) | |
|
|
IQR: interquartile range. Statistically significant. |